DNCA FINANCE 13D and 13G filings for Evelo Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-21 06:10 am Purchase |
2023-02-21 | 13D | Evelo Biosciences, Inc. EVLO |
DNCA FINANCE | 22 4.960% |
22 (New Position) |
Filing |
| 2022-11-21 08:28 am Sale |
2022-11-21 | 13D | Evelo Biosciences, Inc. EVLO |
DNCA FINANCE | 0 0.000% |
-46 (Position Closed) |
Filing |
| 2022-08-23 09:32 am Purchase |
2022-08-23 | 13D | Evelo Biosciences, Inc. EVLO |
DNCA FINANCE | 46 3.630% |
12 (+33.72%) |
Filing |
| 2021-12-28 3:58 pm Purchase |
2021-12-28 | 13D | Evelo Biosciences, Inc. EVLO |
DNCA FINANCE | 34 5.030% |
34 (New Position) |
Filing |